Friday, November 22, 2024

Roche Expands AI Cancer Diagnostics with Digital Pathology

Related stories

Deep Instinct Expands Zero-Day Security to Amazon S3

Deep Instinct, the zero-day data security company built on...

Foxit Unveils AI Assistant in Admin Console

Foxit, a leading provider of innovative PDF and eSignature...

Instabase Names Junie Dinda CMO

Instabase, a leading applied artificial intelligence (AI) solution for...
spot_imgspot_img

Roche announced the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.

The seamless integration is facilitated through Roche’s navify® Digital Pathology enterprise software, an application for the pathologist’s workflow, which now incorporates a diverse range of AI-driven algorithms, creating easy access to third-party innovation. These AI tools are designed to enhance pathology insights, helping benefit cancer patients through precision medicine and enabling targeted treatments.

“We are excited to welcome these new collaborators into our digital pathology ecosystem,” said Jill German, Head of Pathology Lab for Roche Diagnostics. “By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide.”

Also Read: Carterra Ultra™: New Era in Biosensor Drug Discovery

The collaborators are:

  • Deep Bio: Algorithm for prostate cancer detection, grading, and tumour quantification
  • DiaDeep: Algorithms for breast cancer biomarker quantification
  • Lunit: Tumour proportion score (TPS) analysis for non-small cell lung cancer
  • Mindpeak: Algorithms for breast biomarkers and pan tumour PD-L1 for lung, gastric, esophageal, bladder and breast cancers
  • Owkin: Algorithm for the screening of microsatellite stability in colorectal cancer
  • Qritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for metastasis, and screening for colon cancer
  • Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer
  • Stratipath: Algorithm for risk profiling of invasive breast cancer

With these new collaborations and integrations, Roche emphasises its commitment to improving patient outcomes and advancing personalised healthcare by providing scientists and clinicians with the resources they need to deliver precise and effective cancer diagnoses.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img